AFP and hepatocellular carcinoma: In subgroup analysis for OS, lenvatinib tended to differ from sorafenib, with better efficacy (HR [95% CI]) in: (i) presence of macroscopic vein invasion and/or extrahepatic spread (HR 0.87 [0.73–1.04]) vs. absence (HR 1.05 [0.79–1.40]); (ii) high baseline level of alpha-fetoprotein (AFP) ≥ 200 ng/mL (HR 0.78 [0.63–0.98]) vs. low level < 200 ng/mL (HR 0.91 [0.74–1.12]); (iii) HBV-related HCC (HR 0.83 [0.68–1.02]) or HCV (HR 0.91 [0.66–1.26]) vs. non-viral (HR 1.03 [0.47–2.28]) [13].